Bicycle Therapeutics PLC (BCYC) stock
BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3080% below fair value
$3.11−0.09 (-2.81%)
Close on Nov 18, 2026Market cap $217.99MP/E –Yield 0.00%
Bicycle Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Bicycle Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$158.23M. For fiscal 2025 it was -$247.07M. The highest annual figure on record is -$16.21M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$247.07M | – |
| FY2024 | Dec 31, 2024 | -$209.87M | – |
| FY2023 | Dec 31, 2023 | -$189.95M | – |
| FY2022 | Dec 31, 2022 | -$116.65M | – |
| FY2021 | Dec 31, 2021 | -$65.62M | – |
| FY2020 | Dec 31, 2020 | -$51.96M | – |
| FY2019 | Dec 31, 2019 | -$26.30M | – |
| FY2018 | Dec 31, 2018 | -$21.75M | – |
| FY2017 | Dec 31, 2017 | -$16.21M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$13.48M | – |
| Q2 FY2026 | Jun 30, 2026 | -$54.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -$65.48M | – |
| Q4 FY2025 | Dec 31, 2025 | -$24.71M | – |
| Q3 FY2025 | Sep 30, 2025 | -$65.55M | – |
| Q2 FY2025 | Jun 30, 2025 | -$86.60M | – |
| Q1 FY2025 | Mar 31, 2025 | -$70.20M | – |
| Q4 FY2024 | Dec 31, 2024 | -$67.66M | – |
| Q3 FY2024 | Sep 30, 2024 | -$63.85M | – |
| Q2 FY2024 | Jun 30, 2024 | -$46.65M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.72M | – |
| Q4 FY2023 | Dec 31, 2023 | -$54.24M | – |
| Q3 FY2023 | Sep 30, 2023 | -$50.80M | – |
| Q2 FY2023 | Jun 30, 2023 | -$43.11M | – |
| Q1 FY2023 | Mar 31, 2023 | -$41.80M | – |
| Q4 FY2022 | Dec 31, 2022 | -$32.21M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.76M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.30M | – |
| Q1 FY2022 | Mar 31, 2022 | -$27.38M | – |
| Q4 FY2021 | Dec 31, 2021 | -$18.02M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.29M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.28M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.02M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.06M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.68M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.58M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.64M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.76M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.25M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.99M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.29M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.54M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.36M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.96M | – |
See a number that looks wrong?